{'fraction_non_alphanumeric': 0.016260162601626018, 'fraction_numerical': 0.016260162601626018, 'mean_word_length': 5.572815533980583, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Hepatitis C Antibody Positive, RNA Negative

HCV infection is common, with an estimated prevalence of 3.5 million individuals in the United States, of whom approximately 50% are unaware of their infection. Epidemiological data demonstrate a higher prevalence of HCV infection in individuals born between the years 1945 and 1965 because of a significantly increased incidence of HCV transmission in the 1970s and 1980s compared with more recent years. Thus, the Centers for Disease Control and Prevention and the US Preventive Services Task Force both recommend one-time HCV screening of asymptomatic individuals from this birth cohort in addition to directed testing on the basis of traditional risk factors, behaviors, and exposures associated with increased risk for HCV infection. This strategy has been shown to significantly increase the rate at which infected individuals are detected as compared with the conventional risk factor–based approach, which alone misses greater than 50% of infections. The recommendations for HCV testing are based on data showing that screening decreases all-cause mortality and reduces the risk for hepatocellular carcinoma in addition to promoting public health benefits, such as decreasing viral transmission, initiating early treatment to limit HCV-associated morbidity and mortality, and reducing risk behaviors.